A Potential Role for Fructose-2,6-bisphosphate in the Stimulation of Hepatic Glucokinase Gene Expression
Overview
Authors
Affiliations
The effects of fructose-2,6-bisphosphate (F-2,6-P(2)) on hepatic glucokinase (GK) and glucose-6-phosphatase (G-6-Pase) gene expression were investigated in streptozotocin-treated mice, which exhibited undetectable levels of insulin. Hepatic F-2,6-P(2) levels were manipulated by adenovirus-mediated overexpression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. Streptozotocin treatment alone or with infusion of control adenovirus leads to a dramatic decrease in hepatic F-2,6-P(2) content compared with normal nondiabetic mice. This is accompanied by a 14-fold decrease in GK and a 3-fold increase in G-6-Pase protein levels, consistent with a diabetic phenotype. Streptozotocin-treated mice that were infused with adenovirus-overexpressing an engineered 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase with high kinase activity and little bisphosphatase activity showed high levels of hepatic F-2,6-P(2). Surprisingly, these mice had a 13-fold increase in GK protein and a 2-fold decrease in G-6-Pase protein compared with diabetic controls. The restoration of GK is associated with increases in the phosphorylation of Akt upon increasing hepatic F-2,6-P(2) content. Moreover, the changes in levels of F-2,6-P(2) and Akt phosphorylation revealed a pattern similar to that of streptozotocin mice treated with insulin, indicating that increasing hepatic content of F-2,6-P(2) mimics the action of insulin. Because G-6-Pase gene expression was down-regulated only after the restoration of euglycemia, the effect of F-2,6-P(2) was indirect. Also, the lowering of blood glucose by high F-2,6-P(2) was associated with an increase in hepatic nuclear factor 1-alpha protein, a transcription factor involved in G-6-Pase gene expression. In conclusion, F-2,6-P(2) can stimulate hepatic GK gene expression in an insulin-independent manner and can secondarily affect G-6-Pase gene expression by lowering the level of plasma glucose.
Abdallah F, Bazzi S, Akle C, Bahr G, Echtay K Front Endocrinol (Lausanne). 2024; 15:1427058.
PMID: 39377070 PMC: 11456689. DOI: 10.3389/fendo.2024.1427058.
Aiding Cancer's "Sweet Tooth": Role of Hexokinases in Metabolic Reprogramming.
Farooq Z, Ismail H, Bhat S, Layden B, Khan M Life (Basel). 2023; 13(4).
PMID: 37109475 PMC: 10141071. DOI: 10.3390/life13040946.
In Silico Molecular Docking Studies of Phytocompounds From Coleus Amboinicus Against Glucokinase.
Anthony Ammal S, Sudha S, Rajkumar D, Baskaran A, Krishnamoorthy G, Anbumozhi M Cureus. 2023; 15(2):e34507.
PMID: 36874339 PMC: 9984118. DOI: 10.7759/cureus.34507.
Nagano H, Ito S, Masuda T, Ohtsuki S Pharm Res. 2021; 39(7):1561-1574.
PMID: 34811625 DOI: 10.1007/s11095-021-03131-8.
Molecular and cellular regulation of human glucokinase.
Sternisha S, Miller B Arch Biochem Biophys. 2019; 663:199-213.
PMID: 30641049 PMC: 6377845. DOI: 10.1016/j.abb.2019.01.011.